News
Sarepta Reports a Third Gene-Therapy Related Patient Death
The patient, who was being treated with an investigational gene therapy for limb-girdle muscular dystrophy, died of acute liver failure, the same complication responsible for the deaths of two boys taking Sarepta's Duchenne muscular dystrophy treatment Elevidys.
Second patient death from liver failure after Sarepta's Elevidys gene therapy triggers FDA investigation. Stock crashes 41% ...
MedPage Today on MSN1d
Duchenne Gene Therapy Will Undergo Changes After Patient DeathsAt the FDA's request, delandistrogene moxeparvovec (Elevidys), the only approved gene therapy for Duchenne muscular dystrophy ...
Shares of Sarepta Therapeutics have plunged again after the drugmaker reported a second death in connection with its gene therapy for muscular dystrophy. The biotech drugmaker said Sunday it ...
Second patient death reported with gene therapy for muscular dystrophy The U.S. Food and Drug Administration campus in Silver Spring, Md., is photographed, Oct. 14, 2015. Credit: AP/Andrew ...
WASHINGTON (AP) — Shares of Sarepta Therapeutics plunged Monday after the biotech drugmaker reported a second death in connection with its gene therapy for muscular dystrophy.. Sarepta ...
WASHINGTON – Shares of Sarepta Therapeutics plunged Monday after the biotech drugmaker reported a second death in connection with its gene therapy for muscular dystrophy.. Sarepta reported the ...
WASHINGTON (AP) — Shares of Sarepta Therapeutics plunged Monday after the biotech drugmaker reported a second death in connection with its gene therapy for muscular dystrophy.
News-Medical.Net on MSN3d
New cellular entry pathway improves gene therapy outcomesScientists from the Centenary Institute and the University of Sydney have made a landmark discovery that could lead to safer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback